Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS - Free Report) in a research report released on Thursday,Benzinga reports. They currently have a $27.00 target price on the stock. HC Wainwright also issued estimates for Evolus' FY2026 earnings at $0.41 EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.20 EPS and FY2029 earnings at $3.60 EPS.

Several other equities research analysts also recently weighed in on EOLS. Barclays upped their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th.

Evolus Stock Performance

NASDAQ:EOLS traded down $0.30 during midday trading on Thursday, reaching $9.97. 324,829 shares of the company traded hands, compared to its average volume of 652,903. The company has a fifty day moving average price of $12.85 and a 200 day moving average price of $13.27. The firm has a market capitalization of $633.96 million, a price-to-earnings ratio of -10.96 and a beta of 0.97. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a twelve month low of $8.67 and a twelve month high of $17.82.

Insiders Place Their Bets

In related news, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the transaction, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,575 shares of company stock worth $794,369. Company insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Tang Capital Management LLC increased its holdings in shares of Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after purchasing an additional 150,000 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock valued at $34,557,000 after buying an additional 305,300 shares during the period. Caligan Partners LP boosted its stake in shares of Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after buying an additional 498,900 shares during the period. Millennium Management LLC grew its holdings in shares of Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock valued at $15,107,000 after acquiring an additional 308,753 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its holdings in shares of Evolus by 30.9% during the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock worth $14,217,000 after acquiring an additional 304,065 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.